SCHEMBL23095481

SCHEMBL23095481

CCc1ccc(F)c2ncccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.48
L3MBTL1 Q9Y468 7/20 0.47
MPI P34949 2/20 0.47
NPC1 O15118 5/20 0.46
HTT P42858 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR5A P47898 1/20 0.45
ALOX12 P18054 3/20 0.44
PAX8 Q06710 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MITF O75030 2/20 0.43
USP2 O75604 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13462244 0.86 KDM4E (0.56) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL13064176 0.86 KDM4E (0.46) KDM4EL3MBTL1NPC1HTTRAB9A
SCHEMBL14347701 0.85 KDM4E (0.52) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL29661788 0.85 KDM4E (0.52) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL3713797 0.80 KDM4E (0.49) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL9886147 0.80 KMT2A (0.54) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL3787067 0.79 MAPK9 (0.46) KDM4EL3MBTL1MPINPC1HTT
SCHEMBL18910476 0.79 KDM4E (0.47) KDM4EL3MBTL1NPC1HTTRAB9A
SCHEMBL114710 0.79 KDM4E (0.74) KDM4EL3MBTL1NPC1HTTRAB9A
SCHEMBL19990071 0.78 KDM4E (0.70) KDM4EL3MBTL1MPINPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11325930-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2022-05-10 US disclosed
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2021-05-20 US disclosed
EP-3456717-B1 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE GILEAD SCIENCES INC (US) 2021-03-17 EP disclosed
US-10947259-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2021-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325930-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS KDM4E 1288/4885L3MBTL1 3141/4885MPI 2862/4885
US-10947259-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS KDM4E 1288/4885L3MBTL1 3141/4885MPI 2862/4885
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KDM4E 1288/4885L3MBTL1 3141/4885MPI 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.